Skip to content
MARKETS / BALCAO / NPHC
BALCAO · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS · SMALL CAP

Nutra Pharma Corp. NPHC

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$257,612
▲ 4.6% YoY
$-2.0M
$-1.2M
Growth
USD 257,612.00
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.3 · Net income -2.0
4M8M-5M-10M201020122014201620182020202220242025
Compound annual growth
+20.9%
+37.8%
−1.2%
−10.8%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +37.8% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−795 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -567.7% · Net -794.8%
2000%4000%-5000%-10000%201020122014201620182020202220242025
ROE

Not applicable: equity was negative in this period, so return on equity has no meaning.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -1.2
-0.8M-1.6M201020122014201620182020202220242025

Total assetsUSD 584,558.00
EquityUSD -16.8M
CashUSD 12,181.00
Gross debtUSD 9.8M
Net debtUSD 9.7M
Current ratio0.03×

Equity was negative — liabilities exceeded assets. No ratio is shown.

The 16-year record
16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B············0.00.0··
Net income $B−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0··−0.0−0.0−0.0··−0.0−0.0−0.0−0.0·−0.0−0.0−0.0
EPS, diluted $0.000.000.000.00−0.000.000.000.000.00−0.02−0.10−0.08−0.01−0.01−0.01−0.01
Dividend / sh $················
Payout %················
ROE %················
Shares out B7.107.107.067.046.776.965.884.052.030.300.080.041.000.560.330.28

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures · 4 divergences in 66 reconciliationsAUDITED

Reconciled in 12 of 19 fiscal years. 4 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 29 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures4 divergent
ActivityMedicinal Chemicals & Botanical Products
Listed onOTC market
Incorporated inCalifornia
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image